Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Ovarian cancer classification system validated
Fri January 15th - A newly developed method for subtyping ovarian cancer has been validated as accurately predicting disease outcome. More
How euthanasia rates vary across The Netherlands
Fri January 15th - Regions of The Netherlands have recorded a seven-fold unexplained variation in euthanasia rates, according to new analysis published today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Male cancer problem growing

Friday March 20th, 2015

More than 30,000 men in the UK are living with advanced, incurable prostate cancer, new research reveals today.

The figures, released by Macmillan Cancer Support as part of Prostate Cancer Awareness Month, are higher than for any of the other top four cancers and more than one third greater than estimates for breast and colorectal cancer.

Results from the analysis, which is published in the latest edition of the British Journal of Cancer, have led Macmillan to call for improved cancer services to manage the rising number of people who are surviving cancer in the UK.

Research has shown that a man with advanced prostate cancer could survive for an average of four years after diagnosis, while previous Macmillan studies have found that 84% of men with advanced prostate cancer also have at least one other serious health condition that affects further their quality of life.

With a growing cancer population and recent advances in treatment for progressive cancer, the number of men living with advanced, incurable prostate cancer in the UK will continue to increase further, says the study.

Jane Maher, joint chief medical officer at Macmillan Cancer Support, called for the main political parties to commit to improving cancer care and outcomes.

“It is welcome news that survival rates are improving, but as people with advanced prostate cancer are living longer with their illness, their needs now resemble those of people with other long-term conditions,” she said.

“The majority of their treatment might be over, but that doesn’t mean that they don’t need the support of the healthcare system.

“With the ongoing development of a cancer strategy for England and the imminent General Election, this is the time for key decision makers to commit to prioritising cancer care and supporting people living with the disease to lead healthy and fulfilling lives after treatment.”

For information on prostate cancer visit

Tags: Cancer | Menís Health | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)